from Wikipedia, the free encyclopedia
Structural formula
Structural formula of Bufexamac
Non-proprietary name Bufexamac
other names

4-butoxy N -hydroxyphenylacetamid

Molecular formula C 12 H 17 NO 3
External identifiers / databases
CAS number 2438-72-4
EC number 219-451-1
ECHA InfoCard 100.017.683
PubChem 2466
ChemSpider 2372
Wikidata Q412699
Drug information
ATC code
Drug class

Anti-inflammatory drugs

Molar mass 223.27 g mol −1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
no GHS pictograms
H and P phrases H: no H-phrases
P: no P-phrases
Toxicological data

3370 mg kg −1 ( LD 50ratoral )

As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Bufexamac is an anti-inflammatory ( antiphlogistic ) effective drug for the topical treatment of the skin.

Because of the unfavorable benefit-risk ratio (see section side effects ), Bufexamac-containing medicinal products are no longer to be used and are not or no longer on the market in many EU member states.


Bufexamac has been used for dermatitis . It has an anti-inflammatory and antipruritic effect. Preparations containing bufexamac were used for acute and chronic eczema and locally as a combination preparation together with lidocaine as a suppository for hemorrhoidal diseases. The substance has also been used to treat atopic eczema , minor burns , sunburn and itching . In the subacute inflammatory phase, the active ingredient represented a substitute for cortisone . However, reactions and allergies to the active ingredient can also occur, which is why the drug commission of the German medical profession had critically questioned its use for years in more than ten articles and reports since 2000.

Working principle

It is assumed that bufexamac, like indomethacin, intervenes in prostaglandin synthesis by inhibiting cyclooxygenases . The scientific data on this are scanty, however.

Side effects

The active ingredient Bufexamac was known to cause even strong allergic contact eczema, which was often mistakenly mistaken for the original symptom. Therefore, the use should be carefully considered as early as 2000. The Arznei-Telegram had already submitted an “application for risk prevention measures for Bufexamac” to the Federal Health Office responsible at the time on July 10, 1987 . In 2009 the Federal Institute for Drugs and Medical Devices (BfArM) held a hearing on drugs containing bufexamac in all indications according to the step-by-step plan , level II. "The BfArM [...] comes to the conclusion that, according to the current state of scientific knowledge and taking into account available therapeutic alternatives, Bufexamac-containing drugs have harmful effects both in eczema therapy and in proctological indications, which, according to the findings of the medical science go beyond reasonable limits. The benefit / harm ratio is thus judged to be negative overall. ” In April 2010, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) also decided on a negative benefit-risk ratio and withdrawal due to the high risk of triggering contact eczema the Food and drug bufexamac-containing medicines recommended. As a result, the BfArM revoked the approvals; Medicines containing bufexamac could therefore no longer be dispensed in Germany from May 5, 2010.

Trade names


Jomax (D), Parfenac (D, A, CH), Windol (D) and a generic (D)

Combination preparations

Anaesthesin acute (D), Faktu acute (D), Hämoagil (D), Haemo-Exhirud (D), Hämo-Ratiopharm (D), Hexamon (D), Mastu (D)

Individual evidence

  1. Bufexamac data sheet from Sigma-Aldrich , accessed on April 27, 2011 ( PDF ).
  2. BUFEXAMAC CRS data sheet (PDF) at EDQM , accessed on May 6, 2010.
  3. Drug Commission of the German Medical Association on Bufexamac .
  4. Max Gloor, Karl Thoma, Joachim Fluhr: Dermatological external therapy : with special consideration of the magistral recipe . Springer, 2000. ISBN 3-540-67174-9 , p. 349.
  5. Drug Commission of the German Medical Association: Bufexamac - An eczema therapeutic agent that itself often causes allergic contact eczema Deutsches Ärzteblatt, Issue 47 of November 24, 2000.
  6. 8,000 DM for contact allergy according to Bufexamac (PARFENAC) Arznei-Telegram 8/1991, accessed on May 30, 2010.
  7. BfArM : Bufexamac-containing drugs: contact allergic reactions, notification of assessment. Created November 16, 2009, updated May 5, 2010.
  8. ^ European Medicines Agency European Medicines Agency recommends revocation of marketing authorizations for bufexamac. ( Memento from August 20, 2012 in the Internet Archive ) (PDF; 52 kB). Press release from April 22, 2010.
  9. Pharmaceutical newspaper : Bufexamac-containing drugs: revocation of approvals. Drug Commission of the German Pharmacists, notification from May 5, 2010.
  10. Red List Online, as of August 2009.
  11. Swiss Medicines Compendium , as of August 2009.
  12. AGES-PharmMed, as of August 2009.